MINIject® is available at LondonOC

The MINIject® is used to reduce intraocular pressure (IOP) by channelling aqueous humour out of the anterior chamber to the supraciliary space, thus enhancing physiological uveoscleral outflow.

MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space.

As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.

Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form. IOP reduction, through medication or surgery, helps delay disease progression.

Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs. 

MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.

This treatment is potentially best-in-class for its promising long-term efficacy and safety.